Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital

Q4 Medicine
Tanan Bejrananda, Komsan Leetanaporn, N. Pruphetkaew, M. Tanthanuch
{"title":"Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital","authors":"Tanan Bejrananda, Komsan Leetanaporn, N. Pruphetkaew, M. Tanthanuch","doi":"10.2139/ssrn.3897013","DOIUrl":null,"url":null,"abstract":"Abstract Purpose To explore clinical and pathological characteristics of testicular cancer and also identify factors associated with its oncological outcomes. Testicular cancer has a very good prognosis. Actually, we aim to report on 10 years of experience in the real-world practice of treating testicular cancer in a university-based hospital. Methods This is a retrospective cohort study of testicular cancer patients in Songklanagarind hospital; from January 2007 and December 2016, all eligible testicular cancer patients were included. Clinical characteristics (age, physical examination findings, tumour markers, histopathology, clinical stage, and initial treatment) and clinical outcomes were collected. These patients were divided into two groups: seminoma patients (seminomas) and non-seminoma patients (non-seminomas). Clinical characteristics and outcomes of treatment were analysed, and factors associated with oncological outcomes were identified. Results In 45 patients, median age 33 years, with diagnosis of testicular cancer, seminomas and non-seminomas were responsible for 23 (52.8%) and 22 (49%) of the cases, respectively. The median time of follow-up was 80.6 months (range: 1.8 to 120 months). The five-year OS was 94.7% and 57.1% in the seminoma and non-seminoma groups, respectively. For non-seminomas, five-year OS were 71.4%, 50%, and 42.9% in stage Ib–IIIa, IIIb, and IIIc, respectively, and for seminoma they were 92.3% and 100% in stage Ib–IIIa and IIIb, respectively. Multivariable analysis showed that non-seminoma, higher staging, and higher IGCCC risk were associated with poorer survival, significantly (p < 0.05). Conclusions Seminoma has a good prognosis and survival at all stages, whereas, in the non-seminoma group, higher staging and IGCCC risk were independent factors associated with a poorer prognosis.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"77 - 85"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3897013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Purpose To explore clinical and pathological characteristics of testicular cancer and also identify factors associated with its oncological outcomes. Testicular cancer has a very good prognosis. Actually, we aim to report on 10 years of experience in the real-world practice of treating testicular cancer in a university-based hospital. Methods This is a retrospective cohort study of testicular cancer patients in Songklanagarind hospital; from January 2007 and December 2016, all eligible testicular cancer patients were included. Clinical characteristics (age, physical examination findings, tumour markers, histopathology, clinical stage, and initial treatment) and clinical outcomes were collected. These patients were divided into two groups: seminoma patients (seminomas) and non-seminoma patients (non-seminomas). Clinical characteristics and outcomes of treatment were analysed, and factors associated with oncological outcomes were identified. Results In 45 patients, median age 33 years, with diagnosis of testicular cancer, seminomas and non-seminomas were responsible for 23 (52.8%) and 22 (49%) of the cases, respectively. The median time of follow-up was 80.6 months (range: 1.8 to 120 months). The five-year OS was 94.7% and 57.1% in the seminoma and non-seminoma groups, respectively. For non-seminomas, five-year OS were 71.4%, 50%, and 42.9% in stage Ib–IIIa, IIIb, and IIIc, respectively, and for seminoma they were 92.3% and 100% in stage Ib–IIIa and IIIb, respectively. Multivariable analysis showed that non-seminoma, higher staging, and higher IGCCC risk were associated with poorer survival, significantly (p < 0.05). Conclusions Seminoma has a good prognosis and survival at all stages, whereas, in the non-seminoma group, higher staging and IGCCC risk were independent factors associated with a poorer prognosis.
睾丸癌患者的肿瘤预后:一家大学附属医院的10年经验
【摘要】目的探讨睾丸癌的临床病理特点及影响其预后的相关因素。睾丸癌有很好的预后。实际上,我们的目标是报告10年来在大学医院治疗睾丸癌的实际实践经验。方法对宋克兰医院睾丸癌患者进行回顾性队列研究;从2007年1月至2016年12月,纳入所有符合条件的睾丸癌患者。收集临床特征(年龄、体格检查结果、肿瘤标志物、组织病理学、临床分期和初始治疗)和临床结果。这些患者分为两组:精原细胞瘤患者(精原细胞瘤)和非精原细胞瘤患者(非精原细胞瘤)。分析临床特征和治疗结果,并确定与肿瘤结果相关的因素。结果45例患者中位年龄33岁,诊断为睾丸癌,精原细胞瘤和非精原细胞瘤分别占23例(52.8%)和22例(49%)。中位随访时间为80.6个月(1.8 ~ 120个月)。精原细胞瘤组和非精原细胞瘤组的5年OS分别为94.7%和57.1%。对于非精原细胞瘤,5年OS在Ib-IIIa、IIIb和IIIc期分别为71.4%、50%和42.9%,精原细胞瘤在Ib-IIIa和IIIb期分别为92.3%和100%。多变量分析显示,非精原细胞瘤、较高的分期和较高的IGCCC风险与较差的生存率显著相关(p < 0.05)。结论精原细胞瘤在各个阶段均有良好的预后和生存,而在非精原细胞瘤组,较高的分期和IGCCC风险是预后较差的独立因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Forum of Clinical Oncology
Forum of Clinical Oncology Medicine-Oncology
CiteScore
0.50
自引率
0.00%
发文量
3
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信